Full Press Release Details
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
PVLA Neutral Sentiment
Vogt, M. & Skerra, A. (2004) Construction of an artificial receptor protein (“Anticalin”) based on the human apolipoprotein D. ChemBioChem 5, 191-199.
Key Takeaway: The article discusses the construction of an artificial receptor protein known as 'Anticalin' based on human apolipoprotein D. It references a study by Vogt and Skerra published in 2004. The text is primarily placeholder content and does not provide specific insights or findings related to the research.
Price reaction · baseline $22.05 (2025-06-20 close) · 16 other PVLA headline(s) in the window, move may be shared
day 0 close · peak
+2.2%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+106%
120-day peak, hindsight
Typical move
8.9%
average across 5 past catalysts
Cash runway
~58 mo
Minimal dilution risk
Lead asset
PTX-022
Phase 3 · Pachyonychia Congenita